Why the study?
Does candesartan prevent coronary matrix remodeling and alter the expression of MMP and fibrinolytic system molecules in insulin-resistant diabetic rats?
Does candesartan prevent coronary matrix remodeling and alter the expression of MMP and fibrinolytic system molecules in insulin-resistant diabetic rats?
Angiotensin II blockade with candesartan prevents coronary matrix remodeling in insulin-resistant diabetes by modulating the MMP and fibrinolytic systems via TGF-beta1.
Cautions against clinical extrapolation in diabetes; extends mechanistic insights on candesartan in insulin-resistant animal models.
OBJECTIVE: Coronary remodeling based on collagen abnormalities in diabetes might be associated with potential interactions between the matrix metalloproteinase (MMP) system, which regulates extracellular matrix turnover, and the fibrinolytic system, which is involved in the fibrin degradation process. We characterized the profiles of the MMP and fibrinolytic systems in insulin-resistant diabetic rat hearts. METHODS AND RESULTS: By immunohistochemistry and in situ hybridization, transforming growth factor-beta1 (TGF-beta1) expression increased in coronary vessels, the perivascular area, and cardiomyocytes in diabetic rat hearts. Increased expression of plasminogen activator inhibitor-1 (PAI-1) in coronary vessels and the perivascular area was evident in diabetic hearts. In contrast, diabetic hearts exhibited reduced activity and expression of MMP-2 and decreased expression of membrane type-1 MMP (MT1-MMP). Both intravascular and extravascular collagen type I and III immunoreactivity and fibrin deposition were seen in diabetic coronary vessels. These alterations were reversed to nondiabetic levels by the angiotensin II type 1 receptor blocker candesartan, which prevented the development of perivascular fibrosis observed after Masson's trichrome staining. CONCLUSIONS: In addition to upregulation of PAI-1, downregulation of MMP-2 and MT1-MMP might play a crucial role in coronary matrix remodeling in insulin-resistant diabetes. These molecules appear to be regulated by angiotensin II via stimulation of TGF-beta1.
No takes yet. Share an insight, caveat, or question.
Jesmin et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: